Targeting Multiple Hallmarks of Skin Aging: Preclinical and Clinical Efficacy of a Novel Growth Factor-Based Skin Care Serum

Gail K Naughton; Lily I Jiang; Elizabeth T Makino; Robin Chung; Audrey Nguyen; Tsing Cheng; Kuniko Kadoya; Rahul C Mehta

doi:10.1007/s13555-022-00839-2

Targeting Multiple Hallmarks of Skin Aging: Preclinical and Clinical Efficacy of a Novel Growth Factor-Based Skin Care Serum

Dermatol Ther (Heidelb). 2023 Jan;13(1):169-186. doi: 10.1007/s13555-022-00839-2. Epub 2022 Nov 14.

Authors

Gail K Naughton¹, Lily I Jiang², Elizabeth T Makino³, Robin Chung³, Audrey Nguyen³, Tsing Cheng³, Kuniko Kadoya³, Rahul C Mehta⁴

Affiliations

¹ Histogen, Inc., San Diego, CA, USA.
² SGS Stephens, Richardson, TX, USA.
³ Allergan Aesthetics, an AbbVie company, 2525 Dupont Drive, Irvine, CA, 92612, USA.
⁴ Allergan Aesthetics, an AbbVie company, 2525 Dupont Drive, Irvine, CA, 92612, USA. Rahul.Mehta@Abbvie.com.

Abstract

Introduction: The aging process involves numerous biological mechanisms that have been characterized and proposed as the "hallmarks of aging." Targeting the processes and pathways related to these hallmarks of aging that cause and promote skin aging could provide anti-aging benefits. A novel topical growth factor-based skin care serum (A+) was developed using human fibroblast conditioned media. This study aimed to assess the effects of A+ on four hallmarks of aging and its clinical efficacy in skin rejuvenation in subjects with moderate to severe overall facial photodamage.

Methods: Preclinical studies included immunohistochemistry in human ex vivo skin, and gene expression analysis in human 3D skin models. A 24-week, vehicle placebo-controlled study, including FaceQ patient-reported outcomes and skin biopsy analysis, was performed to assess clinical efficacy and tolerability.

Results: Treatment with A+ resulted in reduced expression of cell senescence biomarker H2A.J and upregulation of genes associated with proteasome, autophagy, stemness, and intercellular communication. Clinical assessments showed A+ provided significantly greater reductions in sagging, coarse lines/wrinkles, fine lines/wrinkles, overall photodamage, and overall hyperpigmentation compared with placebo. Subjects felt they appeared younger-looking, reporting a median decrease in self-perceived age of 6 years after 12 weeks of use. Decreased levels of H2A.J and increased expression of key dermal extracellular matrix and epidermal barrier components, including collagen and elastin, were observed in skin biopsy samples.

Conclusion: The present study shows for the first time the potential effects of a topical growth factor-based cosmeceutical on cellular processes related to four hallmarks of aging (cellular senescence, loss of proteostasis, stem cell exhaustion, and altered intercellular communication) to help delay the aging process and restore aged skin. A+ targets the biological mechanisms underlying the aging process itself and stimulates skin regeneration, resulting in rapid and significant clinical improvements.

Keywords: Anti-aging; Cell senescence; Cosmeceuticals; Extracellular matrix; Growth factors; Hallmarks of aging; Skin rejuvenation.